After infusion, CD3+, CD4+, CD56+, CD3+CD56+ cells, and CD4+/CD8+ ratio were significantly increased, resulting in a reduction of HCC recurrence (63). The gene discussed is NCAM1; the disease is hepatocellular carcinoma.